Benzinga · Jul 22, 2026
InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline
Mentari Therapeutics secures $200 million in private financing before merging with InMed Pharmaceuticals to fund migraine therapies.
IN
NASDAQ · INM
InMed Pharmaceuticals Inc.
Healthcare · Biotechnology
$1.43
Up+$0.01 (+0.70%)
Updated Aug 14, 2026, 12:39 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.52M
- P/E ratio
- -0.17
- Dividend yield
- 0.00%
- 52-week range
- $0.58 – $2.50
- Volume
- 24K
- Avg. volume
- 346.51K
Price performance
INM price history
1M range · 21 trading sessions · Daily adjusted prices
INM closed at $1.43 after 21 trading sessions, down 10.06% for the selected period.
- Last close
- $1.43
- Period change
- -10.06%
- Period low
- $1.40
- Period high
- $1.85
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $1.45 | $1.458 | $1.4101 | $1.43 | 24K |
| Aug 12, 2026 | $1.45 | $1.48 | $1.41 | $1.44 | 38.62K |
| Aug 11, 2026 | $1.43 | $1.47 | $1.40 | $1.46 | 56.59K |
| Aug 10, 2026 | $1.35 | $1.4996 | $1.35 | $1.41 | 130.84K |
| Aug 7, 2026 | $1.43 | $1.485 | $1.42 | $1.47 | 54.55K |
| Aug 6, 2026 | $1.42 | $1.46 | $1.40 | $1.43 | 43.33K |
| Aug 5, 2026 | $1.48 | $1.50 | $1.40 | $1.40 | 118.41K |
| Aug 4, 2026 | $1.47 | $1.525 | $1.4674 | $1.49 | 71.28K |
| Aug 3, 2026 | $1.47 | $1.50 | $1.4246 | $1.46 | 63.07K |
| Jul 31, 2026 | $1.55 | $1.56 | $1.4404 | $1.47 | 258.49K |
| Jul 30, 2026 | $1.67 | $1.725 | $1.48 | $1.50 | 261.72K |
| Jul 29, 2026 | $1.66 | $1.70 | $1.62 | $1.67 | 223.09K |
| Jul 28, 2026 | $1.62 | $1.725 | $1.61 | $1.67 | 140.46K |
| Jul 27, 2026 | $1.66 | $1.80 | $1.60 | $1.64 | 337.95K |
| Jul 24, 2026 | $1.88 | $1.90 | $1.69 | $1.71 | 332.28K |
| Jul 23, 2026 | $1.65 | $1.95 | $1.60 | $1.85 | 1.32M |
| Jul 22, 2026 | $2.15 | $2.33 | $1.49 | $1.66 | 52.1M |
| Jul 21, 2026 | $1.53 | $1.54 | $1.50 | $1.54 | 10.29K |
| Jul 20, 2026 | $1.56 | $1.56 | $1.49 | $1.52 | 34.43K |
| Jul 17, 2026 | $1.59 | $1.5928 | $1.52 | $1.52 | 12.72K |
| Jul 16, 2026 | $1.5754 | $1.59 | $1.555 | $1.59 | 11.66K |
Latest INM news
The latest Smart Investors Daily articles mentioning INM.
Stock researchCompany · Overview
INM research
Overview
Company profile and research snapshot.
Company profile
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 29, 2021 | HC Wainwright & Co. | Buy | — |
| Feb 16, 2021 | Roth Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 10, 2026
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-market session. The company's market cap stands at $213.4 million. China Pharma Holding (AMEX:CPHI) shares increased
Yahoo · Jul 6, 2026
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4
Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered into an amendment (the "Amendment") to the previously announced definitive merger agreement (the "Agreement") for an all-stock transaction with Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp., a...
Benzinga · Mar 9, 2026
12 Health Care Stocks Moving In Monday's After-Market Session
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
